Transition Therapeutics (Transition Therapeutics) Treasury Stock : $0.00 Mil (As of Mar. 2016)

View and export this data going back to 2007. Start your Free Trial

What is Transition Therapeutics Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Transition Therapeutics's treasury stock for the quarter that ended in Mar. 2016 was $0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Transition Therapeutics Treasury Stock Historical Data

The historical data trend for Transition Therapeutics's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transition Therapeutics Treasury Stock Chart

Transition Therapeutics Annual Data

Trend

Jun06

Jun07

Jun08

Jun09

Jun10

Jun11

Jun12

Jun13

Jun14

Jun15

Treasury Stock

Get a 7-Day Free Trial

Transition Therapeutics Quarterly Data
	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16
Treasury Stock	Get a 7-Day Free Trial															-	-	-	-	-

Transition Therapeutics Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Transition Therapeutics (Transition Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transition Therapeutics Inc (NAS:TTHI) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.transitiontherapeutics.com

Transition Therapeutics Inc was incorporated on July 6, 1998 as 'Transition Therapeutics and Diagnostics Inc.' The Corporation filed articles of amendment on October 12, 2000 and on October 19, 2000 to create a class of non-voting shares (the 'Class B Shares') and to amend certain attributes of its Common Shares. On November 2, 2000, the Corporation filed articles of amendment to delete its private company restrictions. On December 14, 2000, the Corporation filed articles of amendment to change its name to 'Transition Therapeutics Inc.' The Company's technologies are focused on the treatment of Alzheimer's disease and diabetes. The Corporation operates in one business segment; that is the research and development of therapeutic agents. Its technologies in development include ELND005 (AZD-103) for the treatment of Alzheimer's disease. On April 30, 2013, the Company announced the results of a five-week proof of concept clinical study of TT401 in type 2 diabetic and obese non-diabetic subjects. In the study, TT401, a once weekly administered peptide, demonstrated improvements in glycemic control and reductions in body weight.

Executives

Jack W Schuler	10 percent owner	100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Family Foundation Schuler	10 percent owner	100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045

Transition Therapeutics (Transition Therapeutics) Headlines

From GuruFocus

Hardest Hit Companies of the Day: Transition Therapeutics Inc., Sunesis Pharmaceuticals Inc., GenCorp Inc., Cyclacel Pharmaceuticals Inc., FactSet Research Systems Inc.

By guruek guruek • 12-15-2009